Supplemental Digital Content is available in the text. Deletion of phosphatase and tensin homolog (PTEN) in prostate cancer has been associated with early biochemical recurrence, increased metastatic potential, and androgen independence. We evaluated the status of PTEN loss in a cohort of prostate cancer patients from Jordan. We investigated 71 patients with prostate cancer and 52 control subjects with benign prostatic hyperplasia (BPH). PTEN status was assessed by immunohistochemistry. PTEN mutations on exons 1, 2, 5, and 8 were also evaluated by polymerase chain reaction single-stranded conformation polymorphism (PCR-SSCP). We found PTEN loss in 42 of 71 (59.2%) evaluated prostate cancer cases by immunohistochemistry. In contrast, 51 of 52 BPH (98.1%) cases had an intact PTEN. In a subset of 24 prostate cancer cases evaluated by PCR-SSCP, we found PTEN mutations in 15 (62.5%) cases, whereas 22 (91.7%) of BPH controls lacked PTEN mutations. Exon 5 was the most frequently mutated exon (37.5%). Although the loss of PTEN was not significantly correlated with the Gleason Score (GS) or the World Health Organization (WHO)-International Society of Urological Pathology (ISUP) Grade Group (GG), we found higher frequency of PTEN loss (64%) in patients with GS≥4+3/GG≥3, compared with patients with GS≤3+4/GG≤2 (47.6%). In this first study to address the question of PTEN loss in a predominantly Arab population, we documented the frequency of PTEN loss in prostate cancer patients from Jordan, which was found to be higher than in comparable cohorts from East Asia, and was at the higher end of the range of reported frequency of PTEN loss in respective cohorts from North America and Western Europe. Although there was more frequent PTEN loss in cancers with higher GS/GG, this was not statistically significant.

中文翻译：

---

来自约旦的前列腺癌队列中的 PTEN 丢失

补充数字内容在文本中可用。前列腺癌中磷酸酶和张力蛋白同源物 (PTEN) 的缺失与早期生化复发、转移潜能增加和雄激素无关。我们评估了来自约旦的一组前列腺癌患者的 PTEN 缺失状态。我们调查了 71 名前列腺癌患者和 52 名患有良性前列腺增生 (BPH) 的对照受试者。通过免疫组织化学评估 PTEN 状态。外显子 1、2、5 和 8 上的 PTEN 突变也通过聚合酶链反应单链构象多态性 (PCR-SSCP) 进行评估。我们发现通过免疫组织化学评估的 71 例前列腺癌病例中有 42 例 (59.2%) PTEN 丢失。相比之下，52 例 BPH 中的 51 例 (98.1%) 具有完整的 PTEN。在 PCR-SSCP 评估的 24 例前列腺癌病例中，我们在 15 个 (62.5%) 病例中发现了 PTEN 突变，而 22 个 (91.7%) 的 BPH 对照缺乏 PTEN 突变。外显子 5 是最常突变的外显子 (37.5%)。虽然 PTEN 的丢失与格里森评分 (GS) 或世界卫生组织 (WHO)-国际泌尿病理学会 (ISUP) 等级组 (GG) 没有显着相关性，但我们发现 PTEN 丢失的频率更高 (64%) GS≥4+3/GG≥3的患者，与GS≤3+4/GG≤2的患者相比（47.6%）。在第一项解决主要阿拉伯人群中 PTEN 丢失问题的研究中，我们记录了来自约旦的前列腺癌患者的 PTEN 丢失频率，发现该频率高于来自东亚的可比队列，并且处于较高的水平。来自北美和西欧的相应队列中报告的 PTEN 丢失频率范围的结束。